Fiduciary Trust Co Trims Holdings in Apellis Pharmaceuticals, Inc (NASDAQ:APLS) modernreaders.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from modernreaders.com Daily Mail and Mail on Sunday newspapers.
Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) had its target price trimmed by Wells Fargo & Company from $57.00 to $48.00 in a research note released on Thursday morning, Benzinga reports. The brokerage currently has an equal weight rating on the stock. Other analysts also recently issued reports about the stock. Wedbush dropped their price objective […]
Fadi Fakhouri, MD, PhD, discusses the 1-year results of the NOBLE trial examining use of pegcetacoplan in patients with post-transplant C3G or IC-MPGN.
Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) had its target price trimmed by Wells Fargo & Company from $57.00 to $48.00 in a research report sent to investors on Thursday morning, Benzinga reports. The firm currently has an equal weight rating on the stock. Other equities analysts have also recently issued research reports about the stock. […]
The phase 2 NOBLE trial shows pegcetacoplan reduces disease activity in post-transplant C3G and IC-MPGN, with benefits persisting through the 40-week double-blind period.